Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.

Abstract excerpt

PURPOSE OF REVIEW: Melanoma treatment have been revolutionized since 2010 by the development of immune checkpoint inhibitors, and, for BRAF-mutated melanoma, targeted therapies based on BRAF and MEK inhibitors, which is a model of effective targeted therapy in cancer. However, patients with BRAF wild type cannot benefit for such treatments. In this review, we will focus on the current clinical development of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Clinical Trials, Phase III as Topic
• Share to GTP Phosphohydrolases